Obigen Pharma Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Selling, General & Admin	45.18	48.6	43.17	22.95
Research & Development	248.04	239.14	211.7	196.16
Operating Expenses	293.22	287.74	254.87	219.11
Operating Income	-293.22	-287.74	-254.87	-219.11
Interest Expense	-1.87	-2	-1.62	-0.96
Interest & Investment Income	10.96	11.85	10.86	0.73
Currency Exchange Gain (Loss)	-0.03	0.05	0.09	0.03
Other Non Operating Income (Expenses)	5.96	3.54	0.24	1.11
Pretax Income	-278.2	-274.31	-245.29	-218.21
Net Income	-278.2	-274.31	-245.29	-218.21
Net Income to Common	-278.2	-274.31	-245.29	-218.21
Shares Outstanding (Basic)	106	106	102	76
Shares Outstanding (Diluted)	106	106	102	76
Shares Change (YoY)	39.47%	3.45%	34.82%	-
EPS (Basic)	-2.62	-2.59	-2.39	-2.87
EPS (Diluted)	-2.62	-2.59	-2.39	-2.87
Free Cash Flow	-167.96	-168.76	-127.59	-278.7
Free Cash Flow Per Share	-1.58	-1.59	-1.25	-3.67
EBITDA	-194.46	-191.13	-160.46	-125.33
D&A For EBITDA	98.76	96.6	94.41	93.77
EBIT	-293.22	-287.74	-254.87	-219.11

Source: S&P Global Market Intelligence. Standard template. Financial Sources.